FGFR3 and cancer: It is an oral FGFR1-4 inhibitor and was approved as a single agent in the second-line-or-beyond metastatic setting after platinum-based chemotherapy for patients with cancers that harbor a susceptible FGFR2 or FGFR3 fusion or FGFR3 mutation based on a 40% ORR in the BLC2001 study and a confirmed OS (HR 0.64, 95%CI 0.47–0.88, p = 0.005), PFS (HR 0.58, 95%CI 0.44–0.78, p = 0.0002), and ORR (46% vs. 12%) benefit compared to docetaxel or vinflunine in cohort 1 of the THOR study [19,21].